Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. Oct 2004; 63(10): 1307–1311.
Published online May 6, 2004. doi:  10.1136/ard.2003.019125
PMCID: PMC1754772

Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide


Objective: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.

Methods: In the population based, nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener's granulomatosis, 1969–95, was identified. Through linkage with the Swedish Cancer Register, all subjects in this cohort diagnosed with bladder cancer were identified. Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk. In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.

Results: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively. The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9). Treatment duration longer than 1 year was associated with an eightfold increased risk (OR = 7.7, 95% CI 0.9 to 69). The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.

Conclusion: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.

Full Text

The Full Text of this article is available as a PDF (84K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Talar-Williams C, Hijazi YM, Walther MM, Linehan WM, Hallahan CW, Lubensky I, Kerr GS, Hoffman GS, Fauci AS, Sneller MC. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996 Mar 1;124(5):477–484. [PubMed]
  • Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992 Mar 15;116(6):488–498. [PubMed]
  • Knight Ann, Askling Johan, Ekbom Anders. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer. 2002 Jul 1;100(1):82–85. [PubMed]
  • Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, Hagenbeek A, Stovall M, Banks PM, Adami J, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst. 1995 Apr 5;87(7):524–530. [PubMed]
  • Pedersen-Bjergaard J, Ersbøll J, Hansen VL, Sørensen BL, Christoffersen K, Hou-Jensen K, Nissen NI, Knudsen JB, Hansen MM. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med. 1988 Apr 21;318(16):1028–1032. [PubMed]
  • Plotz PH, Klippel JH, Decker JL, Grauman D, Wolff B, Brown BC, Rutt G. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med. 1979 Aug;91(2):221–223. [PubMed]
  • Beauparlant P, Papp K, Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum. 1999 Dec;29(3):148–158. [PubMed]
  • Ansher AF, Melton JW, 3rd, Sliwinski AJ. Bladder malignancy in a patient receiving low dose cyclophosphamide for treatment of rheumatoid arthritis. Arthritis Rheum. 1983 Jun;26(6):804–805. [PubMed]
  • Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol. 1984;23(5):305–313. [PubMed]
  • Breslow NE, Day NE. Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ. 1987;(82):1–406. [PubMed]
  • Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983 Jan;98(1):76–85. [PubMed]
  • Jayne David, Rasmussen Niels, Andrassy Konrad, Bacon Paul, Tervaert Jan Willem Cohen, Dadoniené Jolanta, Ekstrand Agneta, Gaskin Gill, Gregorini Gina, de Groot Kirsten, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003 Jul 3;349(1):36–44. [PubMed]
  • Cox PJ. Cyclophosphamide cystitis--identification of acrolein as the causative agent. Biochem Pharmacol. 1979 Jul 1;28(13):2045–2049. [PubMed]
  • Brandau S, Böhle A. Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur Urol. 2001 May;39(5):491–497. [PubMed]
  • Fernandes ET, Manivel JC, Reddy PK, Ercole CJ. Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases. J Urol. 1996 Dec;156(6):1931–1933. [PubMed]
  • Khan MA, Travis LB, Lynch CF, Soini Y, Hruszkewycz AM, Delgado RM, Holowaty EJ, van Leeuwen FE, Glimelius B, Stovall M, et al. p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):397–403. [PubMed]
  • Tatsis E, Reinhold-Keller E, Steindorf K, Feller AC, Gross WL. Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum. 1999 Apr;42(4):751–756. [PubMed]
  • Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum. 1997 Apr;40(4):761–768. [PubMed]
  • Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA., Jr Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med. 1987 Jul;83(1):1–9. [PubMed]
  • Radis CD, Kahl LE, Baker GL, Wasko MC, Cash JM, Gallatin A, Stolzer BL, Agarwal AK, Medsger TA, Jr, Kwoh CK. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum. 1995 Aug;38(8):1120–1127. [PubMed]
  • De Ridder D, van Poppel H, Demonty L, D'Hooghe B, Gonsette R, Carton H, Baert L. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol. 1998 Jun;159(6):1881–1884. [PubMed]
  • Stillwell TJ, Benson RC, Jr, DeRemee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum. 1988 Apr;31(4):465–470. [PubMed]

Figures and Tables

Figure 1
 Distribution of the cumulative dose of cyclophosphamide among the 11 cases and their 25 controls in the case-control study nested in a population based cohort of 1065 patients with Wegener's granulomatosis. (Wilcoxon p for difference = 0.01). ...
Figure 2
 Cumulative incidence of bladder cancer by time since first discharge for Wegener's granulomatosis.

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...